Brief: Brickell Biotech Doses First Patient In Second U.S. Pivotal Phase 3 Clinical Study
07/12/2020 12:35
Dec 7 (Reuters) - Brickell Biotech Inc BBI.O :
* BRICKELL BIOTECH DOSES FIRST PATIENT IN SECOND U.S.
PIVOTAL
PHASE 3 CLINICAL STUDY
* BRICKELL BIOTECH INC - TOPLINE RESULTS FROM U.S. PIVOTAL
PHASE 3
PROGRAM ANTICIPATED IN Q4 OF 2021
Source text for Eikon: ID:nGNX97khYQ
Further company coverage: BBI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh Tracks Therapeutics
See all newsBrief: Fresh Tracks Therapeutics Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Fresh Tracks Therapeutics Intends To Seek Judicial Dissolution If Liquidation And Approved By Stockholders
Brief: Fresh Tracks Therapeutics Q3 EPS USD 0.32
Brief: Fresh Tracks Therapeutics Inc On October 10 Received A Notice From Listing Qualifications Department Of Nasdaq
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx